Tempus gets FDA nod for Tempus ECG-Low EF

5 hours ago 1
Using AI technology helps with genetic code prediction research.

Suriphon Singha/iStock via Getty Images

  • Tempus AI (NASDAQ:TEM) said that it has obtained 510((k)) clearance from the U.S. FDA for Tempus ECG-Low EF software.
  • This software utilizes artificial intelligence to help identify patients who may be experiencing a low left ventricular ejection fraction, a measure of

Recommended For You

More Trending News

Read Entire Article